NSABP B-60
NSABP B-60
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy
Protocol Chair: Charles E. Geyer, MD
Protocol Officer: Jame Abraham, MD
Patient Population:
Patients with HER2-positive breast cancer with residual invasive cancer following neoadjuvant therapy
Target Accrual: 275 patients
Status: Recruiting
ClinicialTrials.gov Identifier: NCT04622319
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy
Protocol Chair: Charles E. Geyer, MD
Protocol Officer: Jame Abraham, MD
Patient Population:
Patients with HER2-positive breast cancer with residual invasive cancer following neoadjuvant therapy
Target Accrual: 275 patients
Status: Recruiting
ClinicialTrials.gov Identifier: NCT04622319